IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Prudential PLC

Prudential PLC lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 64,072 shares of the company’s stock after buying an additional 5,086 shares during the period. Prudential PLC owned 0.08% of IDEXX Laboratories worth $31,216,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of IDXX. Ashton Thomas Private Wealth LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter worth approximately $89,000. First Foundation Advisors boosted its holdings in shares of IDEXX Laboratories by 5.1% in the 2nd quarter. First Foundation Advisors now owns 5,158 shares of the company’s stock valued at $2,513,000 after purchasing an additional 250 shares during the last quarter. Oak Thistle LLC grew its stake in shares of IDEXX Laboratories by 58.0% during the 2nd quarter. Oak Thistle LLC now owns 869 shares of the company’s stock valued at $423,000 after buying an additional 319 shares during the period. Ballentine Partners LLC increased its holdings in shares of IDEXX Laboratories by 7.9% during the 2nd quarter. Ballentine Partners LLC now owns 1,282 shares of the company’s stock worth $625,000 after buying an additional 94 shares during the last quarter. Finally, Caprock Group LLC increased its holdings in shares of IDEXX Laboratories by 33.6% during the 2nd quarter. Caprock Group LLC now owns 2,853 shares of the company’s stock worth $1,390,000 after buying an additional 717 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on IDXX shares. Piper Sandler dropped their price target on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a research note on Wednesday, August 14th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. BTIG Research began coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target on the stock. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research report on Monday, June 24th. Finally, Morgan Stanley reduced their target price on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a report on Tuesday, May 14th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $582.25.

IDEXX Laboratories Stock Up 0.7 %

NASDAQ:IDXX opened at $472.35 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. The company has a market capitalization of $38.88 billion, a price-to-earnings ratio of 45.73, a price-to-earnings-growth ratio of 4.02 and a beta of 1.33. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The stock has a 50-day simple moving average of $479.79 and a 200 day simple moving average of $503.54.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter last year, the firm posted $2.67 earnings per share. IDEXX Laboratories’s revenue was up 6.4% compared to the same quarter last year. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.